Skip to main content
Premium Trial:

Request an Annual Quote

FDA to Use Ariana for Genomic Data Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariana Pharma will provide its biomarker data mining technology to the US Food and Drug Administration for its efforts to develop better tools for analyzing genomic data to be used in personalized medicine.

Under a collaborative agreement, FDA will use Ariana's KEM Biomarker technology to analyze data combined with patient characteristics for biomarker signatures that were submitted to FDA through its Voluntary Exploratory Data Submission program, the Paris-based company said today.

"We are looking forward to this collaboration to help the agency systematically analyze all equivalent signatures combining both genomic and phenotypical data," Federico Goodsaid, associate director for operations in genomics in the Office of Clinical Pharmacology at the Center for Drug Evaluation and Research at the FDA, said in a statement.

Ariana Pharma's KEM platform mines and extracts data and enables researchers to make decisions that involve multiple criteria and objectives, the company said.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.